A new study has for the first time elucidated the gut-liver immune regulatory axis jointly maintained by intestinal commensal bacteria and the intestinal endocrine system, and uncovered the fundamental mechanism underlying the body’s nonspecific clearance of drug delivery carriers. It provides a universal solution to the core problem plaguing the delivery field for decades, significantly improves the delivery efficiency and therapeutic effect of tumor-targeted therapy, mRNA therapy, gene editing and other treatments, and blazes a new trail for the clinical translation of biomedical delivery technologies.
The research team led by Professors Wang Yucai, Zhu Shu and Jiang Wei from the University of Science and Technology of China (USTC) published their research paper titled “Commensal-driven serotonin production modulates in vivo delivery of synthetic and viral vectors” in Science on March 19.






